摘要
RECORD研究主要终点是比较在二甲双胍或磺脲类药物治疗的基础上加用罗格列酮的患者与二甲双胍和磺脲类药物联合治疗的患者首次发生心血管住院或死亡的时间是否有差异。结果显示,平均治疗5.5年后,两组的心血管住院或心血管死亡比较差异无统计学意义。在血糖控制方面,以HbA1c来衡量血糖控制,罗格列酮与对照组相比,罗格列酮组患者的血糖控制水平有显著改善。
The aim of RECORD study is to compare the time of first hospitalization due to cardiovascular events or death between patients treated with Metformine ＋ Rosinglitazone, Sulfonylureas ＋ Rosinglitazone with those treated with Metformine ＋ Sulfonylureas. The result showed that, after treated equally for 5.5 years, there was no difference in the time of first hospitalization due to cardiovascular events or death between the two groups. The blood glucose control, as indicated by average HbA1c, was improved in Rosinglitazone group compared with that in the control group.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第1期79-80,共2页
Chinese Journal of Practical Internal Medicine
关键词
2型糖尿病
罗格列酮
心血管死亡
type 2 diabetes
Rosiglitazone
cardiovascular death
作者简介
电子信箱：zhudldr@gmail．com
